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Abstract 
When global clinical trials are carried out, it is important to consider the influence of 
racial and ethnic differences on the outcome. From this viewpoint, global clinical trials 
in East Asia, where racial differences are estimated to be small, are now attracting close 
attention. Under such circumstances, we conducted a survey using the data registered 
with ClinicalTrial.gov to investigate the status of participation of East Asian countries in 
global clinical trials and differences in the regions selected for drug development 
between Japanese enterprises and non-Japanese enterprises. This survey revealed that 
about 90% of all global clinical trials and those involving East Asian countries were 
sponsored by non-Japanese enterprises. Global clinical trials involving only East Asia 
have been accepted as one of the development strategies by Japanese enterprises, but 
this strategy has not spread widely among non-Japanese enterprises. 
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Introduction 
The percentage of approved drugs, whose pivotal data were collected from global 
clinical trials (GCTs), has steadily increased in Japan [1] since the Japanese Ministry of 
Health, Labor and Welfare published the “Basic Principles on Global Clinical Trials” in 
2007 to explain the importance of dose-response data in Japanese subjects and to 
recommend Japan’s early participation in global drug development in response to its 
diversification [2]. In 2012, a supplemental document to the 2007 guideline was also 
published to further clarify appropriate global drug development, specifically focusing 
on East Asia [3]. These guidelines encouraged pharmaceutical enterprises to utilize 
more GCT data to obtain regulatory approval in Japan by providing more options for 
drug development strategies [4]. Similarly, Khin et al. described regulatory and 
scientific issues regarding the use of foreign data in support of new drug applications to 
the US Food and Drug Administration [5]. In 2009, a reflection paper was published to 
help extrapolate the results of clinical studies conducted outside the European Union to 
the EU population [6]. These facts suggest that GCTs have become one of the major 
development strategies for regulatory review and approval of drugs. However, how East 
Asia/Japan, the United States, and Europe contribute to GCTs for regulatory submission 
of drug approval has not been well investigated. Drug development strategies are 
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usually affected by the location of the sponsor’s headquarters [7]. As the importance of 
clinical trials transparency increases, the regulations at 42 CFR 11.22(a) require the 
registration of any applicable clinical trial on ClinicalTrials.gov on December 26, 2007. 
ClinicalTrials.gov has been well-utilized as tracking database of the basic results of 
clinical trials since then. Thus, in this study, we examined the trend of GCTs in terms of 
operational regions on industry-sponsored phase 2 (Ph2) and 3 (Ph3) clinical trials from 
2008 to 2015 and analyzed differences in country selection for GCTs between Japanese 
and non-Japanese pharmaceutical enterprises. 
 
Methods 
1. Definition 
In this study, the following definitions were given:  
GCT: a clinical trial requiring permission from two or more regulatory authorities for 
implementation. East Asia: Japan, Korea, China, Hong Kong, and Chinese Taipei. East 
Asia-involving GCT: GCT in which at least one country/region of East Asia participated. 
US-involving GCT: GCT in which the United States participated. EUR-involving GCT: 
GCT in which any of the three European countries having a large number of clinical 
trials (Germany, France, and the United Kingdom) participated. East Asian GCT: GCT 
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wherein the operational area of the clinical trial is limited to only East Asia. 
 
2. Data source and analysis: 
Data between January 1, 2008 and December 31, 2015 were downloaded from 
“ClinicalTrials.gov” on March 30, 2016. Criteria for data selection were 
industry-funded Ph2 and Ph3 studies. GCTs that had missing information on country 
name and/or start date were excluded from the analysis. Studies involving multiple 
phases (e.g., Ph1/Ph2 or Ph2/Ph3) were analyzed as a later phase study. Annual data 
were analyzed on the basis of the start date. The population ratio was calculated by 
dividing the number of GCTs in each country (the United States, Germany, the United 
Kingdom, France, China, Japan, and Korea) by the national population in 2011, then 
multiplying by one hundred million. When analyzing types of sponsors, the 10 largest 
Japanese enterprise (JEs) and non-Japanese enterprises (nJEs) were selected according 
to 2015 sales in Japan [8], i.e., JEs: Takeda, Astellas, Daiichi Sankyo, Chugai, Otsuka, 
Mitsubishi Tanabe, Eisai, Kyowa Hakko Kirin, Sumitomo Dainippon, and Shionogi and 
nJEs: Pfizer, Merck, Novartis, GSK, Eli Lilly, Bayer, Gilead, Sanofi, BMS, and 
AstraZeneca. Statistical analysis was performed using the Cochran-Armitage test for 
trend, the logistic regression analysis, and Fisher’s exact test, The Cochran–Armitage 
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trend test was performed based on the assumption of data linearity to reveal the trend in 
proportion of Ph2 and Ph3 East Asia-involving GCTs among all GCTs sponsored by 
nJEs and JEs at both Ph2 and Ph3. The logistic regression analysis was performed to 
examine the difference in the region selection for Ph2 and Ph3 clinical trials sponsored 
by nJEs and JEs. Fisher’s exact test was performed to examine the association between 
nJEs and JEs in case of selecting only East Asia as development region. A P value of 
less than 0.05 was considered statistically significant. All statistical analyses were 
conducted using SAS, version 9.4. (SAS Institute, Cary, NC). These analyses were 
performed without formal hypotheses set prior to the conduct of the study, but the 
proposed statistical analyses were conducted as part of the descriptive analyses to 
understand the trends of GCTs in Japan and East Asia. 
 
Results 
Based on the criteria (see “Methods”), 1,310 Ph2 and 1,634 Ph3 trials were selected for 
our surveys. 
1. Number of clinical trials in each phase conducted in each region 
Figure 1 shows changes over time in the percentage of Ph2 and Ph3 GCTs involving 1) 
the United States, 2) any of the three European countries having a large number of 
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clinical trials (Germany, France, and the United Kingdom), or 3) any of the East Asian 
countries/regions. More than 60% of GCTs have been steadily conducted in the United 
States and Europe, whereas in East Asia it was less frequent. However, increases in the 
percentage point (numerical difference of two percentages, hereafter referred to as “pp”) 
of Ph2 and Ph3 GCTs between 2008 and 2015 were larger in East Asia (17.5 pp and 
13.1 pp for Ph2 and Ph3, respectively) than in the United States (3.7 pp and 2.1 pp for 
Ph2 and Ph3, respectively) and Europe (0.2 pp and 8.5 pp for Ph2 and Ph3, 
respectively). 
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Figure 1: Time courses of the percentages of phase 2 and phase 3 GCTs sponsored by 20 companies, 
involving 1) the Unites States, 2) any of the three European countries having a large number of 
clinical trials (Germany, France, and the United Kingdom), or 3) any of the East Asian 
countries/regions. 
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2. Changes over time in the population ratio of the number of clinical trials in 
each phase 
Figure 2 shows the changes over time in the number of Ph2 and Ph3 GCTs and their 
population ratio (the number of GCTs per one hundred million population of each 
country) in the United States, Germany, the United Kingdom, France, China, Japan, and 
Korea. The United States had the most number of GCTs, but the ratio was positioned 
roughly at the middle among the other countries. Korea was close to Japan in terms of 
the number of GCTs. However, the ratio in Korea, which was among the highest for 
countries in Ph3 trials, was markedly higher than that in Japan and similar to that in 
Europe in Ph2 trials. Compared with the United States, the ratio in Japan was lower in 
Ph2 trials but similar in Ph3 trials. The ratio in China remained the lowest among the 
countries. 
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Figure 2: Time courses of the number of GCTs (a,c) and GCTs per 100 million population (b,d) in 
the United States, Germany, France, the United Kingdom, Korea, Japan, and China. a,b: data for 
phase 2 and c,d: data for phase 3 GCTs. GCTs: Global clinical trials. 
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3. Trend of clinical trials sponsored by Japanese enterprises (JEs) and 
non-Japanese enterprises (nJEs) 
To investigate how JEs and nJEs conduct GCTs in the East Asian region, the number 
and percentage of Ph2 and Ph3 East Asia-involving GCTs (see definition in “Methods”) 
were calculated by the type of sponsor (JEs and nJEs). The 10 largest JEs and nJEs (see 
definition in “Methods”) were selected for the comparison according to 2015 sales in 
Japan, the most important brand-name drug market in Asia because the main purpose of 
this research was to investigate the drug development status in Asia. As shown in Figure 
3a, the number of GCTs was markedly larger in nJE-sponsored trials than in 
JE-sponsored ones and had gradually decreased in all types of trials. The total number 
of Ph2 and Ph3 GCTs sponsored by JEs between 2008 and 2015 was 130 and 187, 
respectively, accounting for only 9.9% and 11.4% of all GCTs sponsored by both JEs 
and nJEs. Focusing on East Asia, the total number of Ph2 and Ph3 East Asia-involving 
GCTs sponsored by nJEs during that period was 364 and 691, respectively, accounting 
for 30.8% and 47.8% of all GCTs sponsored by nJEs. Similarly, the total number of Ph2 
and Ph3 East Asia-involving GCTs sponsored by JEs during that period was 34 and 78, 
respectively, accounting for 26.2% and 41.7% of all GCTs sponsored by JEs (Figure 
3b).  
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Figure 3: Different time courses of the number of GCTs and East Asia-involving GCTs sponsored by 
nJEs and JEs. GCTs: Global clinical trials, nJEs: non-Japanese enterprises, JEs: Japanese enterprises, 
Ph2: Phase 2, Ph3: Phase 3. 
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The data indicate that both JEs and nJEs sponsored more Ph3 than Ph2 East 
Asia-involving GCTs. Looking at data from a different perspective, the number of Ph2 
and Ph3 East Asia-involving GCTs sponsored by JEs was 34 and 78, respectively, 
accounting for only 8.5% and 10.1% of all East Asia-involving GCTs sponsored by both 
JEs and nJEs. Furthermore, a significant upward trend was observed in the percentage 
of Ph2 and Ph3 East Asia-involving GCTs among all GCTs sponsored by nJEs (p < 
0.0001) but not in that of Ph2 and Ph3 East Asia-involving GCTs sponsored by JEs 
(Figure 4).  
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Figure 4: Time courses of the percentages of East Asia-involving GCTs among all GCTs sponsored 
by JEs and nJEs. A Cochran–Armitage trend test based on the assumption of data linearity revealed a 
significant upward trend of the percentage of East Asia-involving GCTs sponsored by nJEs at both 
phase 2 and phase 3 (p < 0.0001). GCTs: Global clinical trials, nJEs: non-Japanese enterprises, JEs: 
Japanese enterprises. 
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It should be noted, however, that a significant trend in JEs to select East Asian GCTs 
(see definition in “Methods”) rather than the other types of GCTs such as East 
Asia-involving GCTs and US-involving GCTs was observed. Although only about 10% 
of GCTs were sponsored by nJEs, logistic regression analysis comparing East Asian 
GCTs with other type of clinical trials revealed significant trend in JEs to select East 
Asian GCTs at both Ph2 and Ph3 (Table 1). Furthermore, the total number of Ph2 and 
Ph3 East Asian GCTs sponsored by JEs between 2008 and 2015 was nine and 14, 
respectively, accounting for 26.5% and 17.9% of all East Asia-involving GCTs 
sponsored by JEs. The total number of Ph2 and Ph3 East Asian GCTs sponsored by 
nJEs during that period was 13 and 26, respectively, accounting for 3.6% and 3.8% of 
all East Asia-involving GCTs sponsored by nJEs. The data revealed that the ratio of East 
Asian GCTs in East Asia-involving GCTs by JEs were significantly higher than that of 
nJEs using the Fisher’s exact test (p < 0.0001). 
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Table 1: Difference in the region selection for Ph2 and Ph3 clinical trials sponsored by nJEs and JEs   
 
 Ph2 Ph3 
 nJEs JEs The ratio 
of JEs to 
nJEs a 
P 
value b 
nJEs JEs The ratio 
of JEs to 
nJEs a 
P 
value b 
All GCTs 1180 130 0.11 <.0001 1447 187 0.13 <.0001 
US-involving GCTs 860 78 0.09 <.0001 1035 121 0.12 <.0001 
EUR-involving 
GCTs 
795 68 0.09 <.0001 991 111 0.11 <.0001 
East Asia-involving 
GCTs 
364 34 0.10 <.0001 691 78 0.11 <.0001 
US only clinical 
trials 
474 65 0.14 0.0003 222 45 0.20 0.0076 
East Asian GCTs 13 9 0.69 ― 26 14 0.54 ― 
GCTs: Global clinical trials, nJEs: non-Japanese enterprises, JEs: Japanese enterprises, Ph2: phase 2, 
Ph3: phase 3. 
a: The ratio of JEs to nJEs is calculated by dividing JEs by nJEs, b: P values are calculated using 
logistic regression analysis to compare the ratio of JEs to nJEs of each type of clinical trial with the 
ratio of East Asian GCTs. 
 
  
Discussion: 
This study indicates that the contribution of East Asia to GCTs has gradually increased, 
resulting in further diversification of clinical trials through the addition of new countries 
and regions to GCTs. Nevertheless, the United States and Europe remain major regions 
for implementation of GCTs. Among the East Asian countries, Korea had the most 
active population ratio for the number of GCTs. This could be due to governmental 
efforts, such as the Korea National Enterprise for Clinical Trials (KoNECT), to establish 
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infrastructure for clinical trials [9]. It was quite surprising that both the number and ratio 
of GCT activities in China were the lowest, despite its large market for drugs. The 
China Food and Drug Administration takes approximately 1.5 years to review clinical 
trial applications [10]. This would limit the opportunity of China to participate in GCTs. 
However, in 2015 the Chinese government published a statement that encouraged 
China’s involvement in conducting GCTs [11]. Thus, China may more actively 
implement GCTs in the near future because of its potentially large market. Low ratios in 
Japan and China also suggest the possibility for further improving GCT implementation. 
More guidelines, in addition to those currently available [2, 3, 12, 13], may promote 
East Asia-involving GCTs, thereby providing more drugs to patients. 
Regarding the differences among GCTs, approximately 10% of all East 
Asia-involving GCTs, as well as all GCTs, have been sponsored by JEs, whereas the 
other 90% have been sponsored by nJEs. There are a couple of reasons for the high 
activities of nJE-sponsored East Asia-involving GCTs, including an attractive market 
size, established clinical trial infrastructure that complies with Good Clinical Practice, 
sufficient patients for effective recruitment, and regulatory acceptance of foreign 
population data. More contributions to GCTs by East Asia could be expected because a 
significant upward trend in nJE-sponsored East Asia-involving GCTs was observed. 
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Activities of JE-sponsored East Asia-involving GCTs were still low, but the proportion 
of East Asian GCTs was significantly higher in JEs than in nJEs. These results suggest 
that nJEs seem to include East Asia as one of the many regions wherein they conduct 
GCTs, whereas JEs focus more on the East Asian region to accumulate data in the 
regional population. The differences in country selection for GCTs between JEs and 
nJEs may be attributed to drug class, therapeutic area, market strategy rather than the 
difference of nationality of the enterprise. However, it is noteworthy that the trend for 
East Asian GCTs differed markedly between JEs and nJEs. Recently, the number of own 
subjects enrolled in GCTs has decreased not only in Japan but also in the United States 
and Europe [1, 6, 13]. Proper planning and design of GCTs would be important for 
accumulating scientific evidences for the regulation of drug efficacy and safety. In this 
regard, the ICH E17 guideline [14] is currently under development, with the current 
draft highlighting the importance of considering ethnic factors and consistency of 
evaluation among different populations. It also proposes pooling different populations 
with similar ethnic backgrounds. Also, studies on ethnic factors have showed 
similarities among East Asian populations [15, 16, 17, 18]. GCTs will be further 
promoted by globally implementing the E17 guideline, including the concept of “pooled 
regions” which may apply to East Asia. More active participation of East Asia to GCTs 
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from an exploratory stage will provide better scientific data to understand the impact of 
ethnic factors on drug responses and to more appropriately design a confirmatory GCT. 
We presented an analysis of the region selection for GCTs, with a special focus on 
clinical trial conduct in East Asia. Although the analysis does not consider the outcome 
of the health authority review or the status of clinical trials (e.g., ongoing, completed, or 
terminated) given the purpose of the study, further research is necessary to reveal the 
impact of the clinical trial region on the outcome. Also, further discussions among 
industries, academia, and government will be needed to determine the ideal form of East 
Asian GCTs for efficient drug development. 
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